Center Laboratories (ROCO:4123) Accounts Payable: NT$127 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4123 Center Laboratories Inc ROCO:4123
70 GF Score
Price NT$34.70
GF Value NT$44.89
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Center Laboratories Accounts Payable?

Center Laboratories ROCO:4123 -1.14% 70 Accounts Payable is NT$127 Mil as of Mar. 2026. GuruFocus rates ROCO:4123 with a GF Score™ of 70/100 and a GF Value™ of NT$44.89 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Center Laboratories's Accounts Payable for the quarter that ended in Mar. 2026 was NT$127 Mil.

Center Laboratories's quarterly Accounts Payable increased from Sep. 2025 (NT$108 Mil) to Dec. 2025 (NT$119 Mil) and increased from Dec. 2025 (NT$119 Mil) to Mar. 2026 (NT$127 Mil).

Center Laboratories's annual Accounts Payable declined from Dec. 2023 (NT$142 Mil) to Dec. 2024 (NT$135 Mil) and declined from Dec. 2024 (NT$135 Mil) to Dec. 2025 (NT$119 Mil).

Center Laboratories Accounts Payable Related Terms

Center Laboratories Accounts Payable Historical Data

* Premium members only.

The historical data trend for Center Laboratories's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Center Laboratories Accounts Payable Chart

Center Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.02 94.90 142.39 134.79 119.32

Center Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 132.61 140.17 107.77 119.32 127.44
ROCO:4123
70GF Score
Center Laboratories Inc ROCO:4123
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Center Laboratories Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of NT$127 Mil mean?
Center Laboratories (ROCO:4123) has a Accounts Payable of NT$127 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Center Laboratories and its competitors.
Is Center Laboratories' Accounts Payable too high?
Center Laboratories' current Accounts Payable is NT$127 Mil. Overall, Center Laboratories has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Center Laboratories' Accounts Payable compare to ZTS?
Center Laboratories' Accounts Payable of NT$127 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Center Laboratories and its competitors. Center Laboratories's current Accounts Payable is NT$127 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Center Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Center Laboratories (ROCO:4123) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$44.89, compared to a current price of NT$34.70 — trading 22.7% below its estimated fair value. The current Accounts Payable is NT$127 Mil. Center Laboratories' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Center Laboratories (ROCO:4123), the current Accounts Payable is NT$127 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Center Laboratories (ROCO:4123) Overvalued in 2026?

Based on GuruFocus' analysis, Center Laboratories stock appears to be undervalued. The current stock price of NT$34.70 is trading 22.7% below its estimated GF Value™ of NT$44.89. GuruFocus considers Center Laboratories to be Modestly Undervalued.

Key valuation signals for ROCO:4123:

  • Accounts Payable: NT$127 Mil
  • GF Value™: NT$44.89 vs. price of NT$34.70 (22.7% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the ROCO:4123 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Center Laboratories Business Description

Address No. 3-2, Park Street, 7th floor, Nangang District, Taipei City, TWN, 115
Center Laboratories Inc is engaged in the manufacture and sale of various Western pharmaceuticals, including Western medicine manufacturing, wholesale, and retail. The Company operates through the following segments: Pharmaceutical Division, Biotechnology Venture Capital, and Glac Segment. The Pharmaceutical Division, which generates the majority of revenue, manufactures and sells various Western pharmaceuticals. The Biotechnology Venture Capital segment invests in domestic and foreign biotechnology undertakings, while the Glac Segment manufactures and sells probiotic products. The Company operates in Taiwan, Mainland China, and other regions, with Taiwan generating the majority of revenue.
70GF Score

Get the complete analysis for ROCO:4123

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.70
Price
NT$44.89
GF Value